Table 6.

Occurrence of Cardio‐ and Cerebrovascular as Well as Other Events During the Longitudinal Follow‐Up in the 2 ROADMAP Treatment Groups

	Placebo (n=877)	Olmesartan (n=881)	Odds Ratio (95%‐CI)	P Value
Cardio‐/cerebrovascular morbidity and mortality, n (%)	86 (9.8)	73 (8.3)	0.845 (0.604; 1.182)	0.325
Cardio‐/cerebrovascular morbidity, n (%)	86 (9.8)	73 (8.3)	0.845 (0.604; 1.182)	0.325
Cardiovascular morbidity, n (%)	71 (8.1)	60 (6.8)	0.829 (0.574; 1.196)	0.316
Acute coronary syndrome	23 (2.6)	24 (2.7)	1.025 (0.566; 1.854)	0.936
Coronary revascularisation	22 (2.5)	20 (2.3)	0.895 (0.476; 1.683)	0.731
Silent myocardial infarction	2 (0.2)	2 (0.2)	0.772 (0.101; 5.903)	0.803
Congestive heart failure*	12 (1.4)	3 (0.3)	0.231 (0.063; 0.846)	0.027
New onset of atrial fibrillation	24 (2.7)	17 (1.9)	0.675 (0.355; 1.281)	0.229
Peripheral vascular disease*	6 (0.7)	10 (1.1)	1.840 (0.645; 5.249)	0.254
Cerebrovascular morbidity, n (%)	22 (2.5)	14 (1.6)	0.668 (0.334; 1.336)	0.254
Non fatal stroke	18 (2.1)	7 (0.8)	0.436 (0.178; 1.067)	0.069
Transient ischemic attack	5 (0.6)	7 (0.8)	1.244 (0.377; 4.105)	0.720
Cardio‐/cerebrovascular mortality*, n (%)	2 (0.2)	0 (0.0)
Congestive heart failure	1 (0.1)	0 (0.0)	n.a.	n.a.
Fatal stroke	1 (0.1)	0 (0.0)
Non‐CV related mortality, n (%)	5 (0.6)	3 (0.3)	0.476 (0.108; 2.109)	0.329
Not CV related death	3 (0.3)	2 (0.2)	0.554 (0.087; 3.515)	0.531
Death of unknown cause	2 (0.2)	1 (0.1)	0.369 (0.030; 4.567)	0.437
Total mortality, n (%)	7 (0.8)	3 (0.3)	0.374 (0.093; 1.505)	0.166
Other endpoints, n (%)
End stage renal disease	1 (0.1)	1 (0.1)	1.245 (0.060; 26.006)	0.888
New onset diabetic retinopathy	23 (2.6)	8 (0.9)	0.342 (0.149; 0.782)	0.011

CV indicates cardio‐/cerebrovascular events; n.a., not applicable; ROADMAP, Randomized Olmesartan and Diabetes Microalbuminuria Prevention.

^*Requiring hospital treatment.

^*No death due to sudden cardiac death, myocardial infarction or during cardiovascular surgery was reported.